UBS Group Forecasts Strong Price Appreciation for Zimmer Biomet (NYSE:ZBH) Stock

Zimmer Biomet (NYSE:ZBH) had its target price increased by investment analysts at UBS Group from $120.00 to $130.00 in a research report issued on Thursday, Benzinga reports. The firm currently has a “buy” rating on the medical equipment provider’s stock. UBS Group‘s price objective indicates a potential upside of 23.29% from the company’s previous close.

A number of other equities research analysts have also recently commented on ZBH. Truist Financial set a $114.00 target price on shares of Zimmer Biomet in a research report on Thursday. Zacks Research raised shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 25th. Robert W. Baird set a $104.00 price objective on shares of Zimmer Biomet in a report on Thursday, August 6th. Wells Fargo & Company boosted their target price on Zimmer Biomet from $103.00 to $113.00 and gave the company an “equal weight” rating in a report on Thursday. Finally, Canaccord Genuity Group raised their target price on shares of Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a report on Monday, August 10th. Seven research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and a consensus target price of $111.95.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH traded down $1.41 during midday trading on Thursday, hitting $105.44. 2,660,421 shares of the company’s stock traded hands, compared to its average volume of 2,021,390. The firm has a fifty day moving average of $95.13 and a 200 day moving average of $92.08. The stock has a market capitalization of $20.11 billion, a price-to-earnings ratio of 26.69, a price-to-earnings-growth ratio of 2.34 and a beta of 0.50. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. Zimmer Biomet has a 1 year low of $79.12 and a 1 year high of $112.54.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business had revenue of $2.06 billion during the quarter, compared to analyst estimates of $2.04 billion. During the same period in the prior year, the business posted $1.90 earnings per share. The company’s revenue was up 3.1% on a year-over-year basis. On average, analysts forecast that Zimmer Biomet will post 8.55 earnings per share for the current year.

Insider Activity

In other news, insider Chad Phipps sold 3,000 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the transaction, the insider owned 65,231 shares of the company’s stock, valued at $6,415,468.85. This represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Kevin R. Thornal sold 5,691 shares of the stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The disclosure for this sale is available in the SEC filing. Company insiders own 1.28% of the company’s stock.

Hedge Funds Weigh In On Zimmer Biomet

Institutional investors and hedge funds have recently bought and sold shares of the company. Tacita Capital Inc acquired a new position in Zimmer Biomet in the second quarter valued at approximately $26,000. Ancora Advisors LLC purchased a new position in Zimmer Biomet during the 2nd quarter valued at about $29,000. Elevation Wealth Partners LLC increased its position in shares of Zimmer Biomet by 145.9% in the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 229 shares during the last quarter. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Zimmer Biomet during the first quarter valued at $44,000. Finally, Parvin Asset Management LLC acquired a new stake in shares of Zimmer Biomet during the 2nd quarter worth approximately $47,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Key Headlines Impacting Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q3 results beat expectations. Zimmer Biomet reported adjusted EPS of $1.90 versus the $1.88 consensus and revenue of $2.06 billion versus $2.04 billion expected. Revenue increased 3.1% year over year, providing a fundamental tailwind. Third-quarter earnings results
• Positive Sentiment: Analysts raised price targets. UBS lifted its target to $130 and kept a Buy rating; RBC raised its target to $125 and maintained Outperform. JPMorgan, Citi, Wells Fargo, and Bernstein also increased targets, though their ratings are neutral or equivalent. The revisions suggest improved expectations, but analyst conviction is mixed. UBS rating and target RBC rating and target
• Positive Sentiment: New surgical technology initiative. The company introduced “surgeon-guided autonomy,” a closed-loop framework called “Predict. Perform. Recover.” It could support Zimmer Biomet’s longer-term competitive positioning, though the announcement did not provide a near-term financial impact. Surgeon-guided autonomy announcement
• Neutral Sentiment: Shares recently reached a one-year high after the earnings beat. That reflects positive momentum, but could also leave the stock susceptible to consolidation. The available reports do not point to a specific new negative fundamental catalyst. Zimmer Biomet reaches one-year high

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.